Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells

Journal of Immunology

Volumn 194, Issue 1, 2015, Pages 101-112

  Tan, Ying ^a   Watkins, Amanda A ^a   Freeman, Benjamin B ^a   Meyers, John A ^a   Rifkin, Ian R ^a   Lerner, Adam ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD40 ANTIGEN; CYCLIC AMP; DEOXYRIBONUCLEASE; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 10; INTERLEUKIN 6; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; CD14 ANTIGEN; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERFERON REGULATORY FACTOR; PHOSPHODIESTERASE IV; TLR7 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME INHIBITION; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IGHV GENE; MALE; MIDDLE AGED; MONOCYTE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; VERY ELDERLY; ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; DNA SEQUENCE; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; NUCLEOTIDE SEQUENCE; RADIATION RESPONSE;

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; APOPTOSIS; BASE SEQUENCE; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DEOXYRIBONUCLEASES; FEMALE; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-6; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MONOCYTES; PHOSPHODIESTERASE 4 INHIBITORS; ROLIPRAM; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTOR 9; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919632880     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401854     Document Type: Conference Paper

References (72)

1. Chiorazzi, N., and M. Ferrarini. 2011. Cellular origin(s) of chronic lymphocytic leukemia: Cautionary notes and additional considerations and possibilities. Blood 117: 1781-1791.
2. Chu, C. C., R. Catera, K. Hatzi, X. J. Yan, L. Zhang, X. B. Wang, H. M. Fales, S. L. Allen, J. E. Kolitz, K. R. Rai, and N. Chiorazzi. 2008. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112: 5122-5129.
3. Chu, C. C., R. Catera, L. Zhang, S. Didier, B. M. Agagnina, R. N. Damle, M. S. Kaufman, J. E. Kolitz, S. L. Allen, K. R. Rai, and N. Chiorazzi. 2010. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: Implications for patient outcome and cell of origin. Blood 115: 3907-3915.
4. Catera, R., G. J. Silverman, K. Hatzi, T. Seiler, S. Didier, L. Zhang, M. Hervé, E. Meffre, D. G. Oscier, H. Vlassara, et al. 2008. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol. Med. 14: 665-674.
5. Lanemo Myhrinder, A., E. Hellqvist, E. Sidorova, A. Söderberg, H. Baxendale, C. Dahle, K. Willander, G. Tobin, E. Bäckman, O. Söderberg, et al. 2008. A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 111: 3838-3848.
6. Hamblin, T. J., Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson. 1999. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854.
7. Damle, R. N., T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. L. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, et al. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847.
8. Kawai, T., and S. Akira. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650.
9. Grandjenette, C., A. Kennel, G. C. Faure, M. C. Béné, and P. Feugier. 2007. Expression of functional Toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 92: 1279-1281.
10. Rozková, D., L. Novotná, R. Pytlík, I. Hochová, T. Kozák, J. Bartunková, and R. Spísek. 2010. Toll-like receptors on B-CLL cells: Expression and functional consequences of their stimulation. Int. J. Cancer 126: 1132-1143.
11. Liang, X., E. A. Moseman, M. A. Farrar, V. Bachanova, D. J. Weisdorf, B. R. Blazar, and W. Chen. 2010. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 115: 5041-5052.
12. Spaner, D. E., Y. Shi, D. White, J. Mena, C. Hammond, J. Tomic, L. He, M. A. Tomai, R. L. Miller, J. Booth, and L. Radvanyi. 2006. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20: 286-295.
13. Ntoufa, S., A. Vardi, N. Papakonstantinou, A. Anagnostopoulos, V. Aleporou- Marinou, C. Belessi, P. Ghia, F. Caligaris-Cappio, M.Muzio, and K. Stamatopoulos. 2012. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol. Med. 18: 1281-1291.
14. Spaner, D. E., Y. Shi, D. White, S. Shaha, L. He, A. Masellis, K. Wong, and R. Gorczynski. 2010. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 24: 222-226.
15. Spaner, D. E., and A. Masellis. 2007. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 21: 53-60.
16. Latz, E., A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock. 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5: 190-198.
17. Kim, Y. M., M. M. Brinkmann, M. E. Paquet, and H. L. Ploegh. 2008. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 452: 234-238.
18. Leadbetter, E. A., I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607.
19. Lau, C. M., C. Broughton, A. S. Tabor, S. Akira, R. A. Flavell, M. J. Mamula, S. R. Christensen, M. J. Shlomchik, G. A. Viglianti, I. R. Rifkin, and A. Marshak-Rothstein. 2005. RNA-Associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202: 1171-1177.
20. Viglianti, G. A., C. M. Lau, T. M. Hanley, B. A. Miko, M. J. Shlomchik, and A. Marshak-Rothstein. 2003. Activation of autoreactive B cells by CpG dsDNA. Immunity 19: 837-847.
21. Boulé, M. W., C. Broughton, F. Mackay, S. Akira, A. Marshak-Rothstein, and I. R. Rifkin. 2004. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199: 1631-1640.
22. Vollmer, J., S. Tluk, C. Schmitz, S. Hamm, M. Jurk, A. Forsbach, S. Akira, K. M. Kelly, W. H. Reeves, S. Bauer, and A. M. Krieg. 2005. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202: 1575-1585.
23. Puente, X. S., M. Pinyol, V. Quesada, L. Conde, G. R. Ordónez, N. Villamor, G. Escaramis, P. Jares, S. Bea, M. González-Díaz, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105.
24. Wang, L., M. S. Lawrence, Y. Wan, P. Stojanov, C. Sougnez, K. Stevenson, L. Werner, A. Sivachenko, D. S. DeLuca, L. Zhang, et al. 2011. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365: 2497-2506.
25. Landau, D. A., S. L. Carter, P. Stojanov, A. McKenna, K. Stevenson, M. S. Lawrence, C. Sougnez, C. Stewart, A. Sivachenko, L. Wang, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714-726.
26. Wang, J. Q., Y. S. Jeelall, B. Beutler, K. Horikawa, and C. C. Goodnow. 2014. Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance. J. Exp. Med. 211: 413-426.
27. Lombardi, M. S., A. Kavelaars, and C. J. Heijnen. 2002. Role and modulation of G protein-coupled receptor signaling in inflammatory processes. Crit. Rev. Immunol. 22: 141-163.
28. Lerner, A., and P. M. Epstein. 2006. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem. J. 393: 21-41.
29. Moon, E. Y., and A. Lerner. 2003. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 101: 4122-4130.
30. Tiwari, S., K. Felekkis, E. Y. Moon, A. Flies, D. H. Sherr, and A. Lerner. 2004. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood 103: 2661-2667.
31. Meyers, J. A., J. Taverna, J. Chaves, A. Makkinje, and A. Lerner. 2007. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin. Cancer Res. 13: 4920-4927.
32. Jin, S. L., and M. Conti. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-Activated TNF-Alpha responses. Proc. Natl. Acad. Sci. USA 99: 7628-7633.
33. Jin, S. L., L. Lan, M. Zoudilova, and M. Conti. 2005. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J. Immunol. 175: 1523-1531.
34. Henriques-Pons, A., Q. Yu, S. Rayavarapu, T. V. Cohen, B. Ampong, H. J. Cha, V. Jahnke, J. Van der Meulen, D. Wang, W. Jiang, et al. 2014. Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum. Mol. Genet. 23: 2604-2617.
35. Meyers, J. A., D.W. Su, and A. Lerner. 2009. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J. Immunol. 182: 5400-5411.
36. Kim, D. H., and A. Lerner. 1998. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 92: 2484-2494.
37. Yasuda, K., C. Richez, J. W. Maciaszek, N. Agrawal, S. Akira, A. Marshak- Rothstein, and I. R. Rifkin. 2007. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 178: 6876-6885.
38. Campbell, M. J., A. D. Zelenetz, S. Levy, and R. Levy. 1992. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol. Immunol. 29: 193-203.
39. Brochet, X., M. P. Lefranc, and V. Giudicelli. 2008. IMGT/V-QUEST: The highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36: W503-W508.
40. Bjørgo, E., and K. Taskén. 2006. Role of cAMP phosphodiesterase 4 in regulation of T-cell function. Crit. Rev. Immunol. 26: 443-451.
41. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3: 499.
42. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
43. Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-Acylated lipopeptide. Cell 130: 1071-1082.
44. Fabbri, L. M., B. Beghé, U. Yasothan, and P. Kirkpatrick. 2010. Roflumilast. Nat. Rev. Drug Discov. 9: 761-762.
45. Kawai, T., and S. Akira. 2007. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 13: 460-469.
46. Karin, M., and F. R. Greten. 2005. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5: 749-759.
47. Takaoka, A., H. Yanai, S. Kondo, G. Duncan, H. Negishi, T. Mizutani, S. Kano, K. Honda, Y. Ohba, T. W. Mak, and T. Taniguchi. 2005. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434: 243-249.
48. Kubo-Murai, M., K. Hazeki, K. Nigorikawa, T. Omoto, N. Inoue, and O. Hazeki. 2008. IRAK-4-dependent degradation of IRAK-1 is a negative feedback signal for TLR-mediated NF-kappaB activation. J. Biochem. 143: 295-302.
49. Ferrajoli, A., M. J. Keating, T. Manshouri, F. J. Giles, A. Dey, Z. Estrov, C. A. Koller, R. Kurzrock, D. A. Thomas, S. Faderl, et al. 2002. The clinical significance of tumor necrosis factor-Alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100: 1215-1219.
50. Fayad, L., M. J. Keating, J. M. Reuben, S. O'Brien, B. N. Lee, S. Lerner, and R. Kurzrock. 2001. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome. Blood 97: 256-263.
51. Celhar, T., R. Magalhaes, and A. M. Fairhurst. 2012. TLR7 and TLR9 in SLE: When sensing self goes wrong. Immunol. Res. 53: 58-77.
52. Guiducci, C., M. Gong, Z. Xu, M. Gill, D. Chaussabel, T. Meeker, J. H. Chan, T. Wright, M. Punaro, S. Bolland, et al. 2010. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937-941.
53. Krug, A., S. Rothenfusser, V. Hornung, B. Jahrsdörfer, S. Blackwell, Z. K. Ballas, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-Alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31: 2154-2163.
54. Gilliet, M., W. Cao, and Y. J. Liu. 2008. Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8: 594-606.
55. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303: 1526-1529.
56. Liu, Z., and A. Davidson. 2012. Taming lupus: A new understanding of pathogenesis is leading to clinical advances. Nat. Med. 18: 871-882.
57. Muzio, M., C. Scielzo, M. T. Bertilaccio, M. Frenquelli, P. Ghia, and F. Caligaris-Cappio. 2009. Expression and function of Toll like receptors in chronic lymphocytic leukaemia cells. Br. J. Haematol. 144: 507-516.
58. Jahrsdorfer, B., L. Muhlenhoff, S. E. Blackwell, M. Wagner, H. Poeck, E. Hartmann, R. Jox, T. Giese, B. Emmerich, S. Endres, et al. 2005. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin. Cancer Res. 11: 1490-1499.
59. Fonte, E., B. Apollonio, L. Scarfo, P. Ranghetti, C. Fazi, P. Ghia, F. Caligaris- Cappio, and M. Muzio. 2013. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin. Cancer Res. 19: 367-379.
60. Tiwari, S., H. Dong, E. J. Kim, L. Weintraub, P. M. Epstein, and A. Lerner. 2005. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoidmediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem. Pharmacol. 69: 473-483.
61. Platzer, C., C. Meisel, K. Vogt, M. Platzer, and H. D. Volk. 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-Alpha and cAMP elevating drugs. Int. Immunol. 7: 517-523.
62. Eigler, A., B. Siegmund, U. Emmerich, K. H. Baumann, G. Hartmann, and S. Endres. 1998. Anti-inflammatory activities of cAMP-elevating agents: Enhancement of IL-10 synthesis and concurrent suppression of TNF production. J. Leukoc. Biol. 63: 101-107.
63. Brenner, S., S. Prösch, K. Schenke-Layland, U. Riese, U. Gausmann, and C. Platzer. 2003. cAMP-induced interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J. Biol. Chem. 278: 5597-5604.
64. Bailly, S., B. Ferrua, M. Fay, and M. A. Gougerot-Pocidalo. 1990. Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPSstimulated human monocytes: Role of cyclic AMP. Cytokine 2: 205-210.
65. Prabhakar, U., D. Lipshutz, J. O. Bartus, M. J. Slivjak, E. F. Smith, III, J. C. Lee, and K. M. Esser. 1994. Characterization of cAMP-dependent inhibition of LPSinduced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16: 805-816.
66. Horwood, N. J., T. H. Page, J. P. McDaid, C. D. Palmer, J. Campbell, T. Mahon, F. M. Brennan, D. Webster, and B. M. Foxwell. 2006. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J. Immunol. 176: 3635-3641.
67. Palmer, C. D., B. E. Mutch, S. Workman, J. P. McDaid, N. J. Horwood, and B. M. Foxwell. 2008. Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkappaB activity. Blood 111: 1781-1788.
68. Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
69. Sule, S., A. Rosen, M. Petri, E. Akhter, and F. Andrade. 2011. Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells. PLoS One 6: E17495.
70. Keravis, T., F. Monneaux, I. Yougbaré, L. Gazi, J. J. Bourguignon, S. Muller, and C. Lugnier. 2012. Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. PLoS One 7: E28899.
71. Chugh, P. K. 2012. Lupus: Novel therapies in clinical development. Eur. J. Intern. Med. 23: 212-218.
72. Wittmann, M., and P. S. Helliwell. 2013. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol. Ther. 3: 1-15.